{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-nail-infection/prescribing-information/oral-itraconazole/","result":{"pageContext":{"chapter":{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole","depth":2,"htmlHeader":"<!-- begin field bbc42e60-ea8b-49a9-b96f-c81910752068 --><h2>Oral itraconazole</h2><!-- end field bbc42e60-ea8b-49a9-b96f-c81910752068 -->","summary":"","htmlStringContent":"<!-- begin item 0e69503a-6260-4611-a9db-bd1904115421 --><!-- end item 0e69503a-6260-4611-a9db-bd1904115421 -->","topic":{"id":"1303927b-7e0c-517d-85e9-841c9ac02151","topicId":"d2c6135f-fef1-4a56-80dc-161c93380c7d","topicName":"Fungal nail infection","slug":"fungal-nail-infection","lastRevised":"Last revised in March 2018","chapters":[{"id":"bc563964-f1b0-559d-9f21-380162710ddf","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"dd347390-fb63-5e80-9fab-bd3cc4704341","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0cdd100c-c9d0-5685-980c-52f246d1100e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"886d32db-68df-5055-b459-55404c1f011e","slug":"changes","fullItemName":"Changes"},{"id":"c1cacd2b-dba0-5341-a274-66fd882b2036","slug":"update","fullItemName":"Update"}]},{"id":"9f0a65a3-9309-5a00-a9fa-bda2fb7a49c4","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1121797b-5555-5e24-a9ae-aabc657725dd","slug":"goals","fullItemName":"Goals"},{"id":"aa660497-e222-5e9d-b282-3069500c380f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49df22af-d1aa-56cd-b2dc-30e6ecc84ca8","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a79a5fd4-4f6a-5d37-8714-e4bd3bea76b0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6db25a8b-db82-5b72-bade-fa216c349fd8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2515b15e-47ac-5e93-acaf-588daa2e06f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d257da5b-218f-50fc-96b1-55ec4b44f5cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ccd879d-9979-5f0b-b655-8da37ca04149","slug":"definition","fullItemName":"Definition"},{"id":"20d20421-b2ba-513f-87b5-3fad4f731aa5","slug":"causes","fullItemName":"Causes"},{"id":"3142330a-0287-5835-8a69-857972828fb2","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"29b083db-9488-5407-92df-43f4952d8df3","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d7dd4e0b-6a97-5db7-bfa3-aa690c7974af","slug":"complications","fullItemName":"Complications"},{"id":"3a29be3f-ea9f-56a3-b8d7-78341665856e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4346dd42-e5eb-550e-a004-7c8e7103a196","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b6a7486c-a6d8-5d8b-918c-8610bf76e212","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"eec0a81e-c0c0-5f9d-951e-f19c41cfafaf","slug":"assessment","fullItemName":"Assessment"},{"id":"d84aa70d-b236-5783-9eeb-e1181b1311f8","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"12363e3a-9d3f-54c7-8f68-1145b8f312b3","fullItemName":"Management","slug":"management","subChapters":[{"id":"36068044-ec28-5f59-b737-dd89aa53cca5","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6780cd52-ecfd-5eba-8c7e-66bc71b64ed2","slug":"topical-amorolfine","fullItemName":"Topical amorolfine"},{"id":"7009ace0-8da0-5da4-917e-8900ae3cc390","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"5d413d25-a998-5ee4-ad9d-be6306400282","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"}]},{"id":"0b102b3a-ebce-5c6e-9670-3610defc871d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bc0bd4bc-1b10-52dc-b942-cd4682774d01","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"dc202e28-37b1-5789-a14a-b5a0850d8cf8","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49993e8c-ae7a-5891-bf43-21a6406ce1b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b6aa45b7-d833-599f-8bcc-4d08c6c264bb","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2805cbb7-09b5-5875-a0c1-c501223c6ab3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"595745a2-d654-5e3b-850e-eac6532bd5db","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"74af204e-7571-5d05-963f-0c0614335fbf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"94da5137-b65a-5fa1-a933-bbcaa1a5c10b","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6c728c02-cc7d-57c6-a5e5-63f28452add8","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7ee338d6-156b-4fdc-9a1d-a89a00f85a78 --><h3>Contraindications and cautions</h3><!-- end field 7ee338d6-156b-4fdc-9a1d-a89a00f85a78 -->","summary":"","htmlStringContent":"<!-- begin item e6759ddf-d4bc-482a-8dce-a89a00f858f3 --><!-- begin field a56045ab-c130-4737-999b-a89a00f85a78 --><p><strong>Do not prescribe itraconazole to people with:</strong></p><ul><li>Acute porphyria.</li><li>Ventricular dysfunction or a history of heart failure — itraconazole has been shown to have a negative inotropic effect.</li></ul><p><strong>Prescribe itraconazole with caution in people:</strong></p><ul><li>At high risk of heart failure, including people on treatment with negative inotropic drugs (such as calcium-channel blockers).</li><li>Who are immunocompromised (AIDS, neutropenia, transplants).</li><li>With acute liver disease, or a history of hepatotoxicity with other drugs — consider monitoring liver function tests (LFTs). Advise immediate LFTs if symptoms of possible liver toxicity develop, such as anorexia, nausea, vomiting, fatigue, abdominal pain, or dark urine.</li><li>With renal impairment.</li><li>Taking drugs such as astemizole, pimozide, quinidine, or terfenadine that may prolong the QT interval, as there is a risk of cardiac arrhythmias.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field a56045ab-c130-4737-999b-a89a00f85a78 --><!-- end item e6759ddf-d4bc-482a-8dce-a89a00f858f3 -->","subChapters":[]},{"id":"301bf48c-a24a-5a5d-a934-7842aa8ad5a2","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a6681841-75f4-483c-b88b-a89a00f86cc8 --><h3>Adverse effects</h3><!-- end field a6681841-75f4-483c-b88b-a89a00f86cc8 -->","summary":"","htmlStringContent":"<!-- begin item e6655cf7-45af-4567-8b0d-a89a00f86b72 --><!-- begin field 9c7098ac-4f95-4dcc-8ea6-a89a00f86cc8 --><p><strong>Adverse effects of itraconazole include:</strong></p><ul><li>Gastrointestinal — nausea, abdominal pain (common); vomiting, diarrhoea, constipation, dyspepsia, taste disturbance, flatulence (uncommon). Rarely pancreatitis.</li><li>Hepatobiliary — hyperbilirubinaemia (uncommon). Rarely hepatotoxicity (including acute liver failure).</li><li>Nervous system — headache, dizziness, paraesthesia (uncommon).</li><li>Skin and subcutaneous tissue — rash (common); alopecia, urticaria, pruritus (uncommon).</li><li>Other adverse effects include arthralgia, myalgia, heart failure, erectile dysfunction, menstrual disorders, oedema, tinnitus, visual disturbance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field 9c7098ac-4f95-4dcc-8ea6-a89a00f86cc8 --><!-- end item e6655cf7-45af-4567-8b0d-a89a00f86b72 -->","subChapters":[]},{"id":"7b38353c-0452-550b-b610-9c70010fe5b3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 1e3f87a3-1d50-4acd-85aa-a89a00f87e53 --><h3>Drug interactions</h3><!-- end field 1e3f87a3-1d50-4acd-85aa-a89a00f87e53 -->","summary":"","htmlStringContent":"<!-- begin item a7bbaac1-b40e-49e0-979b-a89a00f87ca3 --><!-- begin field 1535fb7b-12aa-490e-928f-a89a00f87e53 --><p><strong>Itraconazole is metabolized by the cytochrome p450 3A4 (isoenzyme CYP34A) and it interacts with a number of liver enzyme-inducing and liver enzyme-inhibiting drugs.</strong></p><ul><li>Itraconazole levels may be reduced by the following drugs:<ul><li>Carbamazepine, phenobarbital, phenytoin — monitor itraconazole efficacy and increase dose if necessary.</li><li>Rifampicin, rifabutin — monitor itraconazole efficacy and increase dose if necessary.</li><li>St John’s wort — avoid concurrent use.</li></ul></li><li>Itraconazole levels may be increased by the following drugs:<ul><li>HIV protease inhibitors (ritonavir, indinavir) — monitor for adverse effects.</li><li>Clarithromycin and erythromycin — monitor for adverse effects.</li></ul></li><li>Itraconazole may increase levels of the following drugs:<ul><li>Aliskiren — monitor for adverse effects.</li><li>Aripiprazole, quetiapine, risperidone — dose reductions may be necessary.</li><li>Quetiapine — concurrent use with itraconazole is contraindicated. If considered necessary, monitor for adverse effects and adjust dose.</li><li>Phospodiesterase-5 inhibitors (avanafil, sildenafil, vardenafil) — avoid concurrent use with avanafil; reduce dose of sildenafil or vardenafil.</li><li>Benzodiazepines (alprazolam, triazolam, midazolam) — dose reductions may be required.</li><li>Calcium-channel blockers (amlodipine, verapamil) — monitor for adverse effects.</li><li>Colchicine — dose adjustment may be necessary.</li><li>Corticosteroids (budesonide, dexamethasone) — avoid concurrent use.</li><li>Digoxin — monitor the effects of digoxin; digoxin dose may need to be reduced by 50–75%.</li><li>Disopyramide — avoid concurrent use.</li><li>Domperidone — possible increased risk of ventricular arrhythmias. Avoid concurrent use.</li><li>Eplerenone — concurrent use is contraindicated.</li><li>Ergot alkaloids (such as ergotamine and ergometrine) — increased risk of ergotism. Concurrent use is contraindicated.</li><li>Ivabradine — concurrent use is contraindicated.</li><li>Mizolastine — monitor for adverse effects.</li><li>Oral anticoagulants (warfarin, apixaban, dabigatran). Monitor for adverse effects and adjust doses if required.</li><li>Pimozide — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Quinidine — increased risk of torsades de pointes. Concurrent use is contraindicated, but if considered necessary, monitor for adverse effects and reduce dose if required.</li><li>Ranolazine — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Reboxetine — monitor for adverse effects and adjust dose if required.</li><li>Solifenacin — restrict dose of solifenacin to 5 mg daily.</li><li>Statins (lovastatin, simvastatin) — avoid concurrent use.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-nail-infection/references/\">BNF 75, 2018</a>] </p><!-- end field 1535fb7b-12aa-490e-928f-a89a00f87e53 --><!-- end item a7bbaac1-b40e-49e0-979b-a89a00f87ca3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}